Comparison of the effects of dovitinib and bevacizumab on reducing neovascularization in an experimental rat corneal neovascularization model
| Autor: | Berna Şahan, Belkis Ilgaz Yalvac, Signem Eyuboglu, Aylin Yaba, Ferda Ciftci, Bayram Yilmaz |
|---|---|
| Přispěvatelé: | İstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Siğnem Eyüboğlu / 0000-0002-0253-2217, Eyüboğlu Özkardeşler, Siğnem, Siğnem Eyuboğlu / AAR-5224-2020, Siğnem Eyuboğlu / 57210738678, Sahan, B., Ciftci, F., Eyuboglu, S., Yaba Ucar, A., Yılmaz, B., Yalvac, B.I., Yeditepe Üniversitesi |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Vascular Endothelial Growth Factor A
medicine.medical_specialty Tyrosine Kinase Inhibitor Bevacizumab genetic structures medicine.drug_class Administration Topical H&E stain Chemical burn Dovitinib Angiogenesis Inhibitors Quinolones Tyrosine-kinase inhibitor Rats Sprague-Dawley Neovascularization 03 medical and health sciences 0302 clinical medicine Ophthalmology Cornea Burns Chemical medicine Animals Corneal Neovascularization Adult female business.industry medicine.disease eye diseases Rats Disease Models Animal Eye Burns medicine.anatomical_structure Corneal neovascularization 030221 ophthalmology & optometry Benzimidazoles Female sense organs Ophthalmic Solutions medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Popis: | Purpose: To compare the inhibitory effects of dovitinib and bevacizumab for treatment of corneal neovascularization (CNV). Methods: Thirty-nine adult female Sprague Dawley rats weighing 180 to 250 g were used. CNV was induced by silver nitrate in the right eye of each rat. After the chemical burn, the animals were randomized into 5 groups. Group 1 did not receive any chemical substance. Group 2 received dimethyl sulfoxide, group 3 received bevacizumab 5 mg/mL, group 4 received dovitinib 5 mg/mL, and group 5 received bevacizumab 5 mg/mL + dovitinib 5 mg/mL topically administered twice daily for 14 days. On the 14th day, slit-lamp examination was performed, and anterior segment photographs were taken. The corneal neovascular area was measured on photographs as the percentage of the cornea's total area using computer imaging analysis. The corneal sections were stained with hematoxylin and eosin for histopathological examination. Results: A statistically significant decrease in the percentage of CNV was found in all treatment groups (group 3, group 4, and group 5) compared with the control group (group 1) (P < 0.01). A statistically significant difference in the percentage of CNV was found among group 3, group 4, and group 5 (P = 0.003). The percentage of CNV in group 4 was significantly higher than that in group 3 and group 5 (P-1 = 0.004; P-2 = 0.006). There was no statistically significant difference in the percentage of CNV between group 3 and group 5 (P = 0.228). Conclusions: Dovitinib is a newly developed multitargeted tyrosine kinase inhibitor. Topical administration of dovitinib effectively inhibited CNV, but this effect of dovitinib was found less than topical bevacizumab. WOS:000484410200025 31180924 Q2 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|